New Whitepaper Explores How Malvern Instruments Extends a QbD Approach to Instrument Design
‘Extending the boundaries of QbD’, a new whitepaper from Malvern Instruments, explores the application of Quality by Design (QbD) principles to the development of analytical instrumentation and the benefits this brings for users. Taking the example of Malvern’s development of the Mastersizer 3000 particle size analyser, the authors illustrate how instrument companies are aligning with the QbD philosophy. This offers pharmaceutical customers the reassurance of closely similar working practices and products that meet exacting customer standards.
The central idea of QbD is that quality should be built into a product from the outset. It is an approach based on the development of a thorough understanding of the variables that affect performance, quantification of the risks associated with those impacts, and knowledge-based risk mitigation. Taking a similar risk assessment-based QbD approach to instrument design builds consistency and performance into a product from the outset. This thought and knowledge translates directly into an analytical tool that is not only reliable and compliant with regulatory requirements but is also efficient, productive and easy to use.
The starting point for QbD is the clear definition of a target performance profile for the product. The design of the Mastersizer 3000 began with a rigorous assessment of industrial requirements for particle size analysis and, since the product is wrapped by a cycle of continuous improvement, that assessment continues today. The third anniversary of the instrument has been marked with the launch of two new products that deliver even smarter particle sizing. Hydro Sight is a state-of-the-art imaging accessory that makes it quicker and easier to develop and apply the robust particle sizing methods that are essential across industry, by delivering real-time visual monitoring of the dispersion process that precedes every laser diffraction particle size measurement. Hydro SV is a wet dispersion accessory that enables measurement with just a few milligrams of sample.
To download ‘Extending the boundaries of QbD’ from the Malvern website, click here.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance